Business Wire

ASM Global and Leading Finnish Development Company Suvilahden Areena Oy to Partner in Major Helsinki Entertainment Venue Exploration

Share

ASM Global, the world’s largest producer of entertainment experiences, and Suvilahden Areena Oy have announced an unprecedented alliance to propose serving as the lead in the future reimagination of Helsinki’s sprawling iconic and historic Hanasaari power plant built in 1909.

The duo’s aim is to preserve as much of the legendary landmark building while integrating local culture and environment in combination with a state-of-the-art arena and festival area within the development.

ASM Global will anchor the music and live-entertainment venue while exploring incorporating sports programming on a major scale.

ASM Global Europe President Chris Bray said, “Hanasaaren voimala is a major next step for ASM Global in Finland. We already have a strong presence in Scandinavia and are now building on our recent expansion into Helsinki, which includes Kulttuuritalo. We believe that with our unrivalled global network, we will bring the world’s most sought-after concerts and artists to fans in Helsinki.

“Hanasaaren voimala has an exceptional location. The possibility of building a new arena and entertainment hub by the sea with a festival area and an urban culture project is an exciting prospect.”

Suvilahden Areena Oy CEO Timo Nieminen said, “Cooperation with ASM Global strengthens the credibility of our project. We get to use ASM Global’s experience and best practices regarding venue management. Basing the design on strong experience and insights is a prerequisite for a financially feasible project.

“We are now just waiting for the development reservation to be granted by the city. We aim to run a planning process working with the key players in the area, the environs and the city of Helsinki to create a new type of urban culture hub.”

ASM Global’s Stockholm Live operates seven venues in the capital city alone, and in May it announced an operation agreement with the Helsinki Cultural Centre.

ABOUT ASM GLOBAL

ASM Global is the world’s leading producer of entertainment experiences. It is the global leader in venue and event strategy and management—delivering locally tailored solutions and cutting-edge technologies to achieve maximum results for venue owners. The company’s elite venue network spans five continents, with a portfolio of more than 350 of the world’s most prestigious arenas, stadiums, performing arts venues, and convention and exhibition centers, including The Moscone Center, San Francisco; ICC, Sydney Australia; Olympia London; Shenzhen World China; and P&J Live in Aberdeen, U.K.

Follow us on Facebook, Instagram, LinkedIn and Twitter. asmglobal.com

ABOUT SUVILAHDEN AREENA OY

Suvilahden Areena Oy is a Finnish privately owned development company that has applied for a development reservation from the City of Helsinki in March 2023 in order to investigate the feasibility of an event and multipurpose arena intended for culture and events in the Hanasaari power plant area located in Suvilahti, Helsinki. suvilahdenareena.fi.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Jim Yeager
breakwhitelight (for ASM Global)
jim@breakwhitelight.com
Mobile: 818-264-6812

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

CORRECTING and REPLACING PHOTO Decode the Future of AI and Customer Experience at Elevate'25 Digital Innovation Summit18.9.2025 21:23:00 EEST | Press release

Please replace the photo with the accompanying corrected photo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250918928987/en/ Gain insight and advice from firms at the frontier of AI-powered, mobile-first customer experiences. The release reads: DECODE THE FUTURE OF AI AND CUSTOMER EXPERIENCE AT ELEVATE'25 DIGITAL INNOVATION SUMMIT With keynotes from Google Cloud and an independent research firm, Elevate’25 will provide actionable strategies to harness the power of AI and create exceptional experiences for today's mobile-first consumer As unprecedented advancements in AI reshape consumer behavior, digital innovation summit Elevate'25 opened for general registration today. Sponsored by Airship, the exclusive, one-day event is designed to equip business leaders with proven strategies to harness artificial intelligence and mobile-first technology for a decisive competitive advantage. Taking place on October 15, 2025, at the i

Sai Life Sciences Opens Dedicated Facility for Veterinary APIs in Bidar, India18.9.2025 19:22:00 EEST | Press release

Sai Life Sciences (BSE: 544306 | NSE: SAILIFE), an innovator-focused Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the opening of Unit VI, a dedicated facility for Veterinary Active Pharmaceutical Ingredient (API) production, in Bidar, India. Located alongside Unit IV, the company’s flagship API manufacturing site, Unit VI has been established exclusively for veterinary APIs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250918612071/en/ Sai Life Sciences’ Veterinary APIs Unit in Bidar, India. The new facility is designed to meet the highest standards of safety, sustainability, and regulatory compliance, ensuring the production of high-quality APIs for veterinary applications. With this expansion, Sai Life Sciences aims to provide efficient and scalable manufacturing solutions to leading global animal health companies. Making the announcement, Krishna Kanumuri, CEO & Managing Direct

Celltrion Announces Commercial Availability of Omlyclo™ Across Europe at EADV 202518.9.2025 18:45:00 EEST | Press release

Celltrion, Inc. today showcased its longstanding commitment to expanding its biosimilar portfolio in the field of immuno-dermatology by attending the 2025 European Academy of Dermatology and Venereology (EADV) Congress, held 17-20 September in Paris, France. Following the European Commission (EC) approval of Omlyclo™, the first and only omalizumab biosimilar in Europe in May 2024, Omlyclo™ will be commercially available starting in Norway, with subsequent rollouts in European countries. As part of Celltrion’s mission to advance knowledge and understanding in dermatology, especially in chronic spontaneous urticaria (CSU), the company hosted satellite symposium presenting the results of the global Phase III clinical trial of Omlyclo™. The global Phase III clinical trial involved 619 patients with CSU, following them up to week 40. Patients were randomized to receive 300 mg or 150 mg of Omlyclo™, or reference product, every 4 weeks. Starting from week 12, patients who received Omlyclo™ we

Setting the Standard: AMRA Medical Recognized as one of TIME Magazine’s ‘World’s Top HealthTech Companies’18.9.2025 17:40:00 EEST | Press release

AMRA Medical is proud to share its inclusion in the World’s Top HealthTech Companies list, published today by TIME in collaboration with Statista. This recognition positions AMRA among an elite group of global innovators that are leading healthcare transformation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250918372780/en/ AMRA Medical Recognized as one of TIME Magazine’s ‘World’s Top HealthTech Companies’ The selection, which comes just one week after celebrating AMRA’s 15 years of progress and innovation within the body composition space, highlights AMRA’s long-standing commitment to becoming a global leader in health informatics. By delivering detailed, reproducible insights within fat distribution and muscle composition, AMRA’s MRI-based technology is helping clinicians, researchers, and healthcare organizations unlock new levels of understanding across the metabolic and musculoskeletal sectors. “Being recognized by

illumynt, a CNE Direct Company, Is Pleased to Announce the Promotion of Jörg Herbarth to Chief Executive Officer (CEO)18.9.2025 17:30:00 EEST | Press release

illumynt, a CNE Direct company, is pleased to announce the promotion of Jörg Herbarth to Chief Executive Officer (CEO). Jörg has been a key member of illumynt’s executive leadership team since joining in June 2022, most recently serving as Chief Operating Officer. In his new role as CEO, Jörg will spearhead illumynt’s mission to become the number one provider of AI- and data-centric IT Asset Disposition (ITAD) solutions worldwide. Paul Knight, illumynt’s current CEO, will transition to the role of Founder & Chairman. In this capacity, Paul will continue to support the executive team with strategic guidance, while Jörg assumes full leadership of day-to-day operations and global expansion initiatives. Mr. Knight had come out of retirement a year ago to undertake some new initiatives and advance the company's strategic direction. With some necessary changes having taken place- he is thrilled to facilitate this transition to a reduced role again. Under Jörg’s leadership, illumynt will cont

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye